TScan Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TCRX research report →
Range $1 – $1
Price Chart
About the company
TScan Therapeutics, Inc. , a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company’s lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism.
- CEO
- Gavin MacBeath
- IPO
- 2021
- Employees
- 138
- HQ
- Waltham, MA, US
Get TickerSpark's AI analysis on TCRX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $9.27M
- P/E
- -0.17
- PEG
- -0.01
- P/S
- 1.79
- P/B
- 0.50
- EV/EBITDA
- -0.23
- Div Yield
- 0.00%
- Gross Margin
- 86.64%
- Op Margin
- -2246.84%
- Net Margin
- -2219.19%
- ROE
- -140.75%
- ROIC
- -91.54%
Latest fiscal year · YoY change
- Revenue
- $10.32M+266.7%
- Gross Profit
- $7.46M+164.9%
- Op Income
- $-135,813,000
- Net Income
- $-129,766,000-1.8%
- EPS
- $-1.00+12.3%
- OCF Growth
- -22.1%
- FCF Growth
- -21.9%
- 52W High
- $1.47
- 52W Low
- $0.14
- 50D MA
- $0.24
- 200D MA
- $0.79
- Beta
- 1.19
- RSI (14)
- 29
- Avg Volume
- 762.12K
No earnings-call transcripts are available for TCRX yet.
- Free Float
- 85.6%
- Shares Outstanding
- 63.50M
- Float Shares
- 54.36M
of shares held by institutions
59 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Lynx1 Capital Management LP | 8.02M | 0 |
| Bvf Inc/Il | 5.56M | 0 |
| Baker Bros. Advisors LP | 2.78M | 0 |
| Vanguard Capital Management LLC | 2.51M | ▲ 350.06K |
| Vanguard Group Inc | 2.48M | ▲ 157.82K |
| Two Sigma Investments, LP | 1.95M | ▲ 740.60K |
| Acadian Asset Management LLC | 1.69M | ▲ 386.63K |
| Deer Management Co. LLC | 1.25M | 0 |
| Renaissance Technologies LLC | 1.21M | ▼ 118.60K |
| Millennium Management LLC | 1.16M | ▼ 296.67K |
| Jacobs Levy Equity Management, Inc | 1.05M | ▲ 241.45K |
| Citadel Advisors LLC | 1.01M | ▲ 690.70K |
Held by 23 ETFs
Biggest fund positions in TCRX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 1, 26 | MacBeath Gavin | other | 1,000,000 |
| Oct 1, 26 | ZDRAVESKI ZORAN | other | 300,000 |
| May 20, 26 | BAKER BROS. ADVISORS LP | other | 67,000 |
| May 20, 26 | Woods Keith | other | 67,000 |
| May 20, 26 | Nicholson Garry A | other | 67,000 |
| May 20, 26 | Gruia Gabriela | other | 67,000 |
| May 20, 26 | Dorton Katina | other | 67,000 |
| May 20, 26 | Klencke Barbara | other | 67,000 |
| Jan 20, 26 | Amello Jason | other | 350,000 |
| Jan 20, 26 | MacBeath Gavin | other | 1,165,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our TCRX coverage
Recent articles, reports, and earnings notes.
No research on TCRX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate TCRX report →TScan Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
globenewswire.com · Nov 12
Contrasting TScan Therapeutics (NASDAQ:TCRX) and BioNTech (NASDAQ:BNTX)
defenseworld.net · Sep 21
TScan Therapeutics, Inc. (TCRX) Discusses Strategic Refocus on In Vivo Cell Therapy for Solid Tumors and Pausing of Phase III Heme Study Transcript
seekingalpha.com · Sep 2
TScan Reorganizes Pipeline Priorities, Implements Workforce Reduction
benzinga.com · Sep 2
TScan Therapeutics Announces Strategic Reorganization to Focus on in vivo Cell Therapy for Solid Tumors
globenewswire.com · Sep 2
TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Misses Revenue Estimates
zacks.com · Aug 12
TScan Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
globenewswire.com · Aug 12
TScan Therapeutics Announces First Patient Dosed in Phase 3 ALLOHA-2™, a Pivotal Trial Evaluating TSC-101 in Patients with Heme Malignancies
globenewswire.com · Jul 29
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.